 Abeona Therapeutics Inc NASDAQ: ABEO has completed a Type B meeting with the FDA regarding the pivotal trial for its ABO-102 gene therapy for Sanfilippo syndrome type A MPS IIIA. ABO-102 is currently being evaluated in the single-arm Transpher A study in patients with MPS IIIA. 